What is iBio?
iBio is dedicated to creating advanced therapies aimed at improving the quality of life for patients suffering from cardiometabolic disorders and obesity. Their approach prioritizes preserving and building muscle mass, enhancing metabolic function, and ensuring long-term treatment adherence through convenient dosing and improved tolerability, while also serving as a complement to existing therapeutic options. Beyond metabolic health, iBio is actively pursuing a preclinical immuno-oncology pipeline designed to combat aggressive solid tumors, including those affecting the breast, lung, colorectal regions, as well as pancreatic cancer and glioblastoma. The company leverages a sophisticated machine-learning-driven antibody discovery platform, offering core services such as precision epitope engineering, access to a proprietary fully human antibody library, antibody optimization via its StableHu technology, next-generation bispecific design through its EngageTx T-cell engager panel, and enhanced safety and developability with its ShieldTx masking system. The company's leadership is spearheaded by Martin Brenner, DVM, Ph.D., who serves as Chief Executive Officer and Chief Scientific Officer.
How much funding has iBio raised?
iBio has raised a total of $6.5M across 2 funding rounds:
Debt
$350K
Other Financing Round
$6.2M
Debt (2020): $350K with participation from PPP
Other Financing Round (2025): $6.2M, investors not publicly disclosed
Key Investors in iBio
PPP
Public-Private Partnership
What's next for iBio?
With the recent major strategic investment and a substantial total funding amount of $6.6M, iBio is strategically positioned to accelerate its research and development initiatives. The company's focus on a dual pipeline—addressing both cardiometabolic diseases and immuno-oncology—suggests a diversified growth strategy. The capital is anticipated to fuel the progression of its preclinical assets through clinical trials and further enhance its proprietary antibody discovery platform. This significant backing indicates strong investor confidence in iBio's scientific approach and its potential to deliver impactful treatments in areas of high unmet medical need, paving the way for future commercialization and market expansion.
See full iBio company page
